NAV

Bazlitoran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bazlitoran
DrugBank Accession Number
DB14990
Background

Bazlitoran is under investigation in clinical trial NCT02092909 (Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia).

Type
Biotech
Groups
Investigational
Synonyms
  • ALL-P-AMBO-2'-DEOXY-P-THIOCYTIDYLYL-(3'->5')-P-THIOTHYMIDYLYL-(3'->5')-2'-DEOXY-P-THIOADENYLYL-(3'->5')-P-THIOTHYMIDYLYL-(3'->5')-2'-DEOXY-P-THIOCYTIDYLYL-(3'->5')-P-THIOTHYMIDYLYL-(3'->5')-2'-O-METHYL-P-THIOGUANYLYL-(3'->5')-2'-O-METHYL-P-THIOURIDYLYL-(
  • Antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9
  • Bazlitoran
  • DNA, D(P-THIO)(C-T-A-T-C-T-RGM-RUM-M5C-C7G-T-T-C-T-C-T-RGM-RUM)
External IDs
  • IMO-8400

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Bazlitoran sodium1NLR4WAG4U1613607-40-1Not applicable

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2U46M95B5M
CAS number
1378549-07-5

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentDermatomyositis (DM)1
2CompletedTreatmentPsoriasis Vulgaris (Plaque Psoriasis)1
1, 2CompletedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
1, 2CompletedTreatmentWaldenström's Macroglobulinemia (WM)1
1, 2TerminatedTreatmentWaldenström's Macroglobulinemia (WM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 14:40 / Updated at September 28, 2023 05:48